Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22320241 | 0.80 | MEN1 (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23544814 | 0.80 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11957472 | 0.79 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL21436952 | 0.78 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL115434 | 0.78 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL14556243 | 0.78 | LPAR1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2627761 | 0.78 | — | — | |
| SCHEMBL7536260 | 0.78 | KDM4C (0.41) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL9531908 | 0.77 | MEN1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11864935 | 0.77 | MEN1 (0.33) | MEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348859-B1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| EP-2348859-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010039474-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | MEN1 3289/4885KMT2A 2938/4885KDM4C 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.